Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells

Hepatocellular carcinoma (HCC) is one of the most common malignancy-related deaths. p53 mutation in HCC associates with worse clinicopathologic features including therapeutic limitation. A combination of targeted therapy may have some advantages. Akt/mTOR signaling contributes to the regulation of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Patra, Tapas, Meyer, Keith, Ray, Ratna B., Kanda, Tatsuo, Ray, Ranjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580964/
https://www.ncbi.nlm.nih.gov/pubmed/34759291
http://dx.doi.org/10.1038/s41419-021-04371-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580964/
https://www.ncbi.nlm.nih.gov/pubmed/34759291
http://dx.doi.org/10.1038/s41419-021-04371-7

Ejemplares similares